NCT06245915 2025-09-22AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)Arsenal Biosciences, Inc.Phase 1/2 Active not recruiting37 enrolled